YARW Company Profile and Key Details

Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $58.00 to $58.00. The high target offers 127.09% upside. The low target suggests 127.09% downside. The mean target is $58.00. This offers 127.09% upside. Yarrow Bioscience Inc earnings surprise history is a mixed track record. The quarter that ended August 13, 2026, missed forecasts by -80.55%. The prior quarter beat by 2227.78%. Over the last six quarters, Apple has recorded several small beats. These include -99.0% in March 12, 2026.

Average 10-day trading volume of 211.50 thousand shares is significantly above the 3-month average of 100.72 thousand, indicating heightened recent market interest.

Yarrow Bioscience Inc last paid a dividend of 20.1 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $24.19. This means the shares are trading above this model’s fair value.

Our AI price prediction model suggests that Yarrow Bioscience Inc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -22.94%, with price expected at $19.68 by October 09, 2026, within a range of $16.94 to $22.35 3-Month Outlook: Projected fall of -32.46%, reaching $17.25 by December 24, 2026, with a range of $16.98 to $17.52. 1-Year Outlook: Projected gain of 1225.53%, with price at $338.54 by September 24, 2027, within a range of $338.20 to $338.77.

Valuation shows Yarrow Bioscience Inc trading at a premium to the broader market with a P/E of -1.09. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $58.00, suggesting 127.09% upside. Our AI forecast model points to short-term weakness (-22.94% over two weeks), a medium-term fall (-32.46% over three months), and a longer-term gain (1225.53% over one year), with expected trading ranges indicating moderate volatility.

Yarrow Bioscience Inc trades at a P/E ratio of -1.09, slightly below the S&P 500 average, with a price-to-sales ratio of 0.91 and a price-to-book ratio of 0.99 suggesting the stock is closer to book value. The P/FCF stands at -0.03, also above market averages.

Yarrow Bioscience Inc (NASDAQ:YARW) closed at $25.54 USD, losing -$0.53 (-2.03%) from the previous close of $26.07. The stock is currently mid-range between its 52-week high and low $16.00 and $46.95. With a market capitalization of about $439.19 thousand, Yarrow Bioscience Inc is classified as a micro-cap and shows higher-than-market volatility (beta ~2.07). Key stats such as the average daily volume over the past year has been around 77.84 thousand shares, trading with heavier-than-usual volume. Headquartered in New Haven, CT, Yarrow Bioscience Inc operates in the Healthcare sector and the Biotechnology industry. Led by CEO Rebecca Velez Frey, the company employs approximately 10 people and listed since July 28, 2026. Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases.